Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against SARS-CoV-۲ Omicron variant

سال انتشار: 1400
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 256

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:


تاریخ نمایه سازی: 5 تیر 1401

چکیده مقاله:

SARS-CoV-۲ is a single-stranded RNA virus which belongs to the own coronavirus circle of relatives andreasons Covid-۱۹. Omicron variant is a SARS-CoV-۲ variant and was first reported on November ۹, ۲۰۲۱.Moreover, World Health Organization (WHO) declared it a cause for concern on November ۲۶, ۲۰۲۱. In thisproject, we designed a multi-epitope vaccine candidate targeting the spike glycoprotein of the Omicronvariant. Spike glycoprotein is the largest protein of four structural proteins discovered in coronaviruses. Thisprotein is incredibly immunogenic, and spike anti-protein antibodies are discovered in improved SARS andCovid-۱۹ instances, and most COVID-۱۹ vaccine development efforts in the reaction to the COVID-۱۹pandemic aim to set off the immune response against the spike protein. In addition to being effective againstthe Omicron variant, the bioinformatics vaccine presented in the current project is also effective against othervariants of the former coronavirus. Furthermore, the vaccine is expected to be effective against other variantsthat we will encounter in the future; because the epitopes used in this present research are found via theexisting coronavirus sequences, which were sequenced in different countries since the beginning of thepandemic. It means that these sequences are somehow conserved in the coronavirus genomic sequence. Theproposed vaccine candidate was evaluated for various characteristics such as antigenicity, allergenicity,toxicity, physical and chemical properties, secondary and tertiary structure, and its interaction with theimmune system using the docking technique. Finally, the suggested vaccine candidate has passed all thecomputational tests and is now acknowledged as a viable coronavirus vaccine candidate.


Esmaeil Roohparvar Basmenj

Biophysics Department, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, IRAN

Seyed Shahriar Arab

Biophysics Department, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, IRAN